Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Stock Short Interest Declines 46.1%

Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Free Report) was the target of a significant drop in short interest during the month of October. As of October 30th, there was short interest totaling 77,889 shares, a drop of 46.1% from the October 15th total of 144,402 shares. Based on an average daily volume of 77,098 shares, the days-to-cover ratio is currently 1.0 days. Approximately 7.4% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

BJDX has been the subject of several analyst reports. Wall Street Zen lowered Bluejay Diagnostics from a “hold” rating to a “sell” rating in a research note on Monday, September 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Monday, September 21st. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Get Our Latest Stock Report on BJDX

Bluejay Diagnostics Stock Performance

NASDAQ:BJDX opened at $2.61 on Monday. The stock has a market cap of $2.92 million, a price-to-earnings ratio of -0.09 and a beta of 0.92. The business’s 50-day simple moving average is $3.07 and its 200 day simple moving average is $6.95. Bluejay Diagnostics has a one year low of $1.84 and a one year high of $28.00.

Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($1.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($3,520.00) by $3,518.28.

Bluejay Diagnostics Company Profile

(Get Free Report)

Bluejay Diagnostics, Inc. is a medical technology company focused on developing rapid, point-of-care diagnostic testing solutions. The company’s technology is designed to provide healthcare professionals with timely information from blood samples, supporting clinical decision-making in settings where conventional laboratory testing may take longer. Its primary product is the Symphony system, a diagnostic platform consisting of an analyzer and disposable test cartridges. The platform is intended to measure biomarkers in whole blood and is being developed for applications including the assessment and management of serious medical conditions such as sepsis and other critical-care situations.

See Also

Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.